CELG Celgene Corporation

125.07
+1  (1%)
Previous Close 124.45
Open 124.50
Price To book 14.68
Market Cap 97.30B
Shares 777,966,000
Volume 1,883,724
Short Ratio 2.00
Av. Daily Volume 3,801,710

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2017.
OTEZLA
Ankylosing Spondylitis
Phase 3 trial to be initiated 2017.
OTEZLA
Scalp Psoriasis
Phase 3 to be initiated 2017.
RPC-4046
Eosinophilic Esophagitis (EoE)
Phase 3 data due 2018.
REVLIMID - ROBUST
First-line ABC Diffuse large B-cell lymphoma (DLBCL)
Phase 3 data released at ASH 2016.
REVLIMID - REMARC
Maintenance in Patients with Diffuse large B-cell lymphoma (DLBCL) responding to R-CHOP to induction therapy
Phase 3 data due 2017.
REVLIMID - RELEVANCE
Newly Diagnosed Follicular Lymphoma
Phase 3 data released at ASH December 2016.
REVLIMID - MYELOMA XI
Induction and Maintenance in ASCT Eligible
Phase 3 trial enrolling.
REVLIMID - MM-026 ARUMM
Multiple Myeloma - Maintenance Post-VMP induction
Phase 3 data due 2019.
REVLIMID - MAGNIFY NHL-010
Untreated Activated B-Cell Diffuse large B-cell lymphoma (DLBCL)
Phase 3 data due 2019.
REVLIMID - MAGNIFY NHL-008
Relapsed or Refractory Indolent Lymphoma
Phase 3 data released at ASH 2016.
REVLIMID - CLL-002 CONTINUUM
Maintenance in Second-line Chronic Lymphocytic Leukemia (CLL)
Phase 3 enrolling. Data due 2017.
REVLIMID - AUGMENT NHL-007
Relapsed or Refractory Follicular Lymphoma
Phase 3 trial to complete enrollment 1H 2017. Data due 2018.
MM-007 OPTIMISMM
Multiple Myeloma - refractory
Phase 3 enrolling. Data due 2018.
Ozanimod - TRUE NORTH
Ulcerative Colitis
Phase 3 data released February 17, 2017 - primary endpoint met.
Ozanimod - SUNBEAM
Relapsing Multiple Sclerosis
Phase 3 - primary endpoint met.
OTEZLA - PSA-006
Psoriatic Arthritis
Phase 3 enrolling. Data due 2018.
OTEZLA - BCT-002 RELIEF
Behçet’s Disease
sNDA filing due 2017
OTEZLA
Once daily formulation
Phase 3 enrollment to be completed 2H 2017.
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 enrollment to be completed 2H 2017.
Luspatercept - BELIEVE
b -thalassemia
Phase 3 enrolling. Data due 2018.
GED-0301 (CD-003)
Crohn’s disease
Phase 3 enrolling. Data due 2018.
GED-0301 (CD-002)
Crohn’s disease
Global Phase 3 study for AG-221 initiated October 2015. Continue to enroll through 2016.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Phase 3 enrolling. Data due 2018.
CC-486 (Oral Azacitidine) - CC-486-AML-001
Post induction AML Maintenance
Phase 3 enrolling.
CC-486 (Oral Azacitidine)
Low risk/INT-1 transfusion-dependent MDS
Phase 3 data due 2017.
ABRAXANE - PANC-003 apact
Adjuvant Therapy in Surgically Resected Pancreatic Cancer
Phase 3 enrolling. Data due 2018.
ABRAXANE - NSCL-003 abound.sqm
First-line late stage Squamous Non-small cell lung cancer (NSCLC)
Phase 3 data due 2017.
ABRAXANE - NSCL-003 abound.70+
Elderly Non-small cell lung cancer (NSCLC)
Phase 3 enrolling.
ABRAXANE - NSCL-003
Maintenance After Induction in Squamous Non- Small Cell Lung Cancer
Phase 3 data due 2018.
ABRAXANE - IMpower 131 ( I/O Combo)
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2018.
ABRAXANE - IMpower 130 ( I/O Combo)
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2018.
ABRAXANE - IMPassion ( I/O Combo)
Triple Negative Metastatic Breast Cancer
Phase 3 data due 2Q 2017.
Ozanimod - RADIANCE
Relapsing Multiple Sclerosis
Phase 2 data due 2017. Phase 3 trial to be initiated 2018.
OTEZLA
Ulcerative Colitis
Phase 2 to be initiated in 2017.
Luspatercept
Myelofibrosis
Phase 2 data due 2017.
GED-0301
Ulcerative Colitis
Phase 2 data are 1H 2017. Announced November 1, 2016 that it has discontinued further enrollment.
Demcizumab plus carboplatin and pemetrexed - DENALI
First-line non-squamous Non-small cell lung cancer (NSCLC)
Phase 2 data released April 10, 2017 - primary endpoint not met.
Demcizumab plus Abraxane - YOSEMITE
First-line pancreatic cancer
Phase 2 data due 2017.
CC-486 with fulvestrant
ER+, HER2 breast cancer
Phase 3 trial planned.
Marizomib
Glioblastoma (GBM) cancer
Pivotal trial to be initiated in 2017. ASCO Poster Session June 5, 2017. Abstract 7513.
JCAR017
Relapsed/refractory B cell non-Hodgkin lymphoma - cancer
Phase 1/2 data due 2017.
Durvalumab - FUSION
Relapsed and/or refractory multiple myeloma (RRMM), myelodysplastic syndromes and AML
Phase 1/2 trials ongoing. Pivotal program to be initiated 2017.
CC-122
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM)
Phase 1 interim data released November 30, 2016 - 78% ORR. Pivotal trial to be initiated 2017. Updated data at ASCO June 5, 2017. Abstract 3010
bb2121
Relapsed/refractory multiple myeloma
PDUFA date August 30, 2017 under priority review.
Enasidenib (AG-221)
Relapsed/Refractory IDH2 mutant-positive Acute Myeloid Leukemia -
Approved February 22, 2017.
REVLIMID
Multiple myeloma (MM) - autologous stem cell transplant (ASCT)